Fall Katja, Strömberg Fredrik, Rosell Johan, Andrèn Ove, Varenhorst Eberhard
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Scand J Urol Nephrol. 2008;42(4):352-7. doi: 10.1080/00365590802078583.
To evaluate the reliability of cause-of-death diagnoses among prostate cancer patients.
Information from death certificates obtained from the Swedish Death Register was compared with systematically reviewed medical records from the population-based Swedish Regional Prostate Cancer Register, South-East Region. In total, 5675 patients were included who had been diagnosed with prostate cancer between 1987 and 1999 and who had died before 1 January 2003.
The proportion of prostate cancer cases classified as having died from prostate cancer was 3% higher in the official death certificates than in the reviewed records [0.03, 95% confidence interval (CI) 0.02 to 0.04]. Overall agreement between the official cause of death and the reviewed data was 86% (95% CI 85 to 87%). A higher accuracy was observed among men with localized disease (88%, 95% CI 87 to 89%), aged 60 years or younger at death (96%, 95% CI 93 to 100%), or who had undergone curative treatment (91%, 95% CI 88 to 95%). This study indicates a relatively high reliability of official cause-of-death statistics of prostate cancer patients in Sweden.
Mortality data obtained from death certificates may be useful in the evaluation of large-scale prostate cancer intervention programmes, especially among younger patients with localized disease.
评估前列腺癌患者死因诊断的可靠性。
将从瑞典死亡登记处获取的死亡证明信息与基于瑞典东南部地区前列腺癌登记处的系统回顾医疗记录进行比较。总共纳入了5675例在1987年至1999年间被诊断为前列腺癌且在2003年1月1日前死亡的患者。
在官方死亡证明中，被归类为死于前列腺癌的前列腺癌病例比例比经审查的记录高3%[0.03，95%置信区间（CI）0.02至0.04]。官方死因与审查数据之间的总体一致性为86%（95%CI 85至87%）。在患有局限性疾病的男性（88%，95%CI 87至89%）、死亡时年龄在60岁及以下（96%，95%CI 93至100%）或接受过根治性治疗的男性（91%，95%CI 88至95%）中观察到更高的准确性。这项研究表明瑞典前列腺癌患者官方死因统计的可靠性相对较高。
从死亡证明获得的死亡率数据可能有助于评估大规模前列腺癌干预项目，特别是在患有局限性疾病的年轻患者中。
